SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations and a published abstract regarding Xcytrin(R) (motexafin gadolinium) Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial data. The presentations and publications are part of the proceedings at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO) that will be held June 1-5, 2007, at McCormick Place in Chicago, IL.
The presentations and published abstracts are as follows: Sunday, June 3, 2007 Session: Central Nervous System Tumors Oral Presentation: Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials. Abstract #2010: 3:00 - 3:15 p.m. Location: S100a Presenter: William Shapiro, M.D., Barrow Neurological Institute, Phoenix,AZ Session: Central Nervous System Tumors Poster Presentation: Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS). Abstract #2037: 8:00 a.m. - 12:00 p.m.; Discussion: 11:00 a.m. - 12:00 p.m. Poster Display Location: S102a; Discussion: S100a Presenter: Minesh P. Mehta, M.D., University of Wisconsin Motexafin Gadolinium Published Abstract Abstract #18001 Title: A phase II trial of motexafin gadolinium (MGd) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum-based chemotherapy: Preliminary results of Stage 1
Pharm acyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress related proteins. Its multifunctional mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R), has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.
Web site: http://www.pharmacyclics.com/
Ticker Symbol: (NASDAQ-NMS:PCYC)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company